Nkarta to Participate at Upcoming Investor Conference
Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company focused on engineered natural killer cell therapies for cancer, will participate in the 21st Annual Needham Virtual Healthcare Conference on April 12, 2022, at 4:30 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company focused on engineered natural killer cell therapies for cancer, will participate in the 21st Annual Needham Virtual Healthcare Conference on April 12, 2022, at 4:30 p.m. ET. A webcast of the presentation will be available in the Investors section of Nkarta’s website and can be accessed after the live event for approximately four weeks. Nkarta specializes in developing off-the-shelf NK cell therapies designed for outpatient treatments, leveraging advanced cell engineering and cryopreservation technologies.
Details
News Market Reaction – NKTX
The recorded move for NKTX in the trading session of this news was -6.73%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SOUTH SAN FRANCISCO, Calif., April 08, 2022 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat cancer, today announced its participation at an upcoming investor conference:
21st Annual Needham Virtual Healthcare Conference
April 12, 2022
4:30 p.m. ET – presentation
A simultaneous webcast of the event will be available on the Investors section of Nkarta’s website, www.nkartatx.com, and a replay will be archived on the website for approximately four weeks.
About Nkarta
Nkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer (NK) cell therapies for cancer patients. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered for deep anti-tumor activity and intended for broad access in the outpatient treatment setting. For more information, please visit the company’s website at www.nkartatx.com.
Nkarta Media/Investor Contact:
Greg Mann
Nkarta, Inc.
gmann@nkartatx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.